The product pipeline
MOLOGEN AG is developing innovative medicines and vaccines on the basis of its own MIDGE® and dSLIM® technology platforms and through the use of its own human, allogeneic tumor cell bank.
We focus our research and development activities on diseases for which there is a great medical demand: the treatment of cancer and the prevention of severe infectious diseases.
Our product pipeline is aligned accordingly:
The products' mechanism of action is based on the research results of the three Nobel Prize winners for Medicine in 2011.
